Some clinical potentials of chlorophenoxyisobutyrate (clofibrate) therapy (hyperlipidemia-angina pectoris-blood sludging-diabetic neuropathy)
- 1 May 1968
- journal article
- research article
- Published by Elsevier in Metabolism
- Vol. 17 (5) , 457-473
- https://doi.org/10.1016/0026-0495(68)90068-1
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- CLOFIBRATE IN GLAUCOMAThe Lancet, 1967
- Hypolipidemic effect of chlorophenoxyisobutyrate in adult‐onset diabetes mellitusClinical Pharmacology & Therapeutics, 1966
- The Separate Hypolipoproteinemic Effects of Dextrothyroxine and Ethyl ChlorophenoxyisobutyrateJournal of Clinical Endocrinology & Metabolism, 1964
- Effects of Cholesterol-Lowering Drugs on Serum TriglyceridesPublished by American Medical Association (AMA) ,1964
- Reduction of Cholesterol and Lipids in Man by Ethyl p-ChlorophenoxyisobutyrateAnnals of Internal Medicine, 1963
- A study of the effect of atromid therapy in exudative diabetic retinopathyJournal of Atherosclerosis Research, 1963
- Effect of Atromid on Requirements of WarfarinJournal of Atherosclerosis Research, 1963
- The effects of atromid on the metabolism of adrenal steroids and on plasma lipid fractionsJournal of Atherosclerosis Research, 1963
- EFFECT OF ATROMID AND ETHYL CHLOROPHENOXYISOBUTYRATE ON ANTICOAGULANT REQUIREMENTSThe Lancet, 1963
- Settling of Sludge in Human PatientsAngiology, 1958